Shares in Insys Therapeutics (NSDQ:INSY) jumped yesterday after the company reported positive data for its investigational epinephrine nasal spray designed as a needle-free treatment for anaphylaxis.
In a 60-person pharmacokinetics study, early data show that the company’s intranasal formulation of epinephrine boasted similar bioavailability to epinephrine delivered via Mylan’s EpiPen auto-injector.
Get the full story at our sister site, Drug Delivery Business News.
The post Insys Therapeutics reports positive preliminary data for allergy nasal spray appeared first on MassDevice.
from MassDevice https://ift.tt/2HRElnP
Cap comentari:
Publica un comentari a l'entrada